Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation study of the Lybrido/Lybridos demarcation formula in women with FSIAD
NL-OMON40620Recruiting
- Sponsor
- Companion Diagnostics
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of sildenafil + testosterone, Lybridos and Placebo-COD Research Private Ltd in female sexual arousal disorder (FSAD) (3 arms), sponsored by Companion Diagnostics. Primary endpoint: Change from placebo in frequency of satisfactory sexual events following study medication intake. Started Jan 2014; status: recruiting.
02
Drugs
sildenafil + testosteroneLybridosPlacebo-COD Research Private Ltd
03
Conditions
female sexual arousal disorder (FSAD)
Beyond the preview
Go deeper on NL-OMON40620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40620.